Creative Medical Technology Holdings logo

Creative Medical Technology HoldingsNASDAQ: CELZ

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

06 November 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$5.75 M
-80%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-75%vs. 3y high
35%vs. sector
338.46
-55%vs. 3y high
96%vs. sector

Price

after hours | 84 min ago
$4.30+$0.30(+7.50%)

Dividend

No data over the past 3 years
$8.00 K-$1.56 M

Analysts recommendations

Institutional Ownership

CELZ Latest News

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
globenewswire.com24 July 2024 Sentiment: POSITIVE

PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence (AI) with the Company's proprietary human induced pluripotent stem cells (“iPSC”). This iPSC clinical line is part of the Company's iPSCelz® program.

Creative Medical Technology Holdings Provides Corporate Update
globenewswire.com10 July 2024 Sentiment: POSITIVE

PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update highlighting recent developments of note.

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
globenewswire.com24 June 2024 Sentiment: POSITIVE

PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin.

Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Zacks Investment Research07 March 2024 Sentiment: POSITIVE

Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.

What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Zacks Investment Research22 September 2023 Sentiment: POSITIVE

Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Zacks Investment Research13 April 2023 Sentiment: POSITIVE

Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.

3 Methods for Finding Penny Stocks to Buy and Hold
PennyStocks13 April 2023 Sentiment: POSITIVE

Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What type of business is Creative Medical Technology Holdings?

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

What sector is Creative Medical Technology Holdings in?

Creative Medical Technology Holdings is in the Healthcare sector

What industry is Creative Medical Technology Holdings in?

Creative Medical Technology Holdings is in the Biotechnology industry

What country is Creative Medical Technology Holdings from?

Creative Medical Technology Holdings is headquartered in United States

When did Creative Medical Technology Holdings go public?

Creative Medical Technology Holdings initial public offering (IPO) was on 06 November 2015

What is Creative Medical Technology Holdings website?

https://www.creativemedicaltechnology.com

Is Creative Medical Technology Holdings in the S&P 500?

No, Creative Medical Technology Holdings is not included in the S&P 500 index

Is Creative Medical Technology Holdings in the NASDAQ 100?

No, Creative Medical Technology Holdings is not included in the NASDAQ 100 index

Is Creative Medical Technology Holdings in the Dow Jones?

No, Creative Medical Technology Holdings is not included in the Dow Jones index

When was Creative Medical Technology Holdings the previous earnings report?

No data

When does Creative Medical Technology Holdings earnings report?

Next earnings report date is not announced yet